Tarsus Pharmaceuticals (TARS)

Healthcare · Biotechnology
$73.16 +1.30% on the day Market cap $3.0B 52-week range $53.89 to $91.53 Prices as of Oct 11, 2026

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Tarsus Pharmaceuticals's free cash flow was negative in fiscal 2025, so a cash-flow reverse DCF doesn't give a meaningful answer. The Modeling tab works from revenue and margins instead.

Fundamental grade

D

Five factors scored 1 to 9 from TARS's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation2
Profitability0
Growth9
Financial health7
Cash efficiency0

Results from SEC filings

Fiscal years, from Tarsus Pharmaceuticals's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.

Fiscal year20212022202320242025
Revenue$57M$26M$17M$183M$451M
Net income-$14M-$62M-$136M-$116M-$66M
Free cash flow$3M-$50M-$119M-$85M-$22M
EPS (diluted)-$0.67-$2.52-$4.62-$3.07-$1.59
Operating margin-21.3%-242.9%-820.5%-65.9%-15.7%

Where the revenue comes from

Revenue by products, fiscal 2024. Every breakdown, year by year.

Product sales, net$180M98%
License fees and collaboration revenue$3M2%

Superinvestors who own TARS

From each investor's latest 13F filing (what a 13F shows). 2 of the investors we track hold it.

InvestorLast quarterValue% of portfolioQuarter
Hersh Cohen
ClearBridge Investments
Added $35M0.03%Q2 2026
Cliff Asness
AQR Capital Management
Added $3M0.00%Q2 2026

Insider buying

Open-market purchases by Tarsus Pharmaceuticals's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.

No open-market insider purchases of TARS in the last 12 months. Most insider activity is selling and option exercises, which aren't shown here.

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when TARS trades at or below it.

$

New accounts get 7 days of Pro, price alerts included. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters

Questions

Are Tarsus Pharmaceuticals insiders buying the stock?

No open-market insider purchases of TARS in the last 12 months, according to SEC Form 4 filings.

Which superinvestors own Tarsus Pharmaceuticals?

2 of the superinvestors Investingly tracks hold TARS in their latest 13F, including Hersh Cohen, Cliff Asness.

Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.